ZA913922B - Method for preventing a second heart attack employing an hmg coa reductase inhibitor - Google Patents

Method for preventing a second heart attack employing an hmg coa reductase inhibitor

Info

Publication number
ZA913922B
ZA913922B ZA913922A ZA913922A ZA913922B ZA 913922 B ZA913922 B ZA 913922B ZA 913922 A ZA913922 A ZA 913922A ZA 913922 A ZA913922 A ZA 913922A ZA 913922 B ZA913922 B ZA 913922B
Authority
ZA
South Africa
Prior art keywords
preventing
coa reductase
reductase inhibitor
heart attack
hmg coa
Prior art date
Application number
ZA913922A
Other languages
English (en)
Inventor
Adeoye Y Olukotun
Y Olukotun Adeoye
John C Alexander
C Alexander John
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of ZA913922B publication Critical patent/ZA913922B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA913922A 1990-06-11 1991-05-23 Method for preventing a second heart attack employing an hmg coa reductase inhibitor ZA913922B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53636790A 1990-06-11 1990-06-11

Publications (1)

Publication Number Publication Date
ZA913922B true ZA913922B (en) 1992-02-26

Family

ID=24138206

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913922A ZA913922B (en) 1990-06-11 1991-05-23 Method for preventing a second heart attack employing an hmg coa reductase inhibitor

Country Status (7)

Country Link
EP (1) EP0461548A3 (xx)
JP (1) JPH04243839A (xx)
AU (1) AU7719291A (xx)
CA (1) CA2042526A1 (xx)
HU (1) HU911931D0 (xx)
IE (1) IE911910A1 (xx)
ZA (1) ZA913922B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
CA2300165A1 (en) * 1997-08-26 1999-03-04 Merck & Co., Inc. Cholesterol-lowering therapy
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
EP1514543A1 (en) 1997-08-29 2005-03-16 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
RS50377B (sr) 1999-08-30 2009-11-10 Sanofi-Aventis Deutschland Gmbh., Inhibitori sistema renin-angiotenzin i njihova primena
WO2001078747A1 (de) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Verwendung von cse-hemmern zur behandlung von herzinsuffizienz
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56164116A (en) * 1980-05-23 1981-12-17 Sankyo Co Ltd Remedy for ischemic cardiopathy
JPS58109416A (ja) * 1981-12-21 1983-06-29 Sankyo Co Ltd 虚血性心疾患治療剤
ES2009918A6 (es) * 1987-05-22 1989-10-16 Squibb & Sons Inc Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo.
PT87540B (pt) * 1987-05-22 1992-09-30 Squibb & Sons Inc Processo para a preparacao de inibidores da reductase de hmg-coa contendo fosforo e novos intermediarios
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin

Also Published As

Publication number Publication date
EP0461548A2 (en) 1991-12-18
IE911910A1 (en) 1991-12-18
AU7719291A (en) 1991-12-12
CA2042526A1 (en) 1991-12-12
JPH04243839A (ja) 1992-08-31
EP0461548A3 (en) 1992-09-30
HU911931D0 (en) 1991-12-30

Similar Documents

Publication Publication Date Title
AU1022795A (en) Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
AU7729694A (en) Method for inhibiting metalloproteinase expression
AU5495090A (en) Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
AU5144896A (en) A corrosion-inhibiting cleaner for tin-plated steel
AU9031591A (en) A bioartificial liver
AU2058992A (en) HMG-COA reductase inhibitors
AU7075391A (en) Zinc-manganese alloy coated steel sheet
HUP9602929A2 (en) Method and arrangement for suppressing reflection of a fixed target at range finding on the principe of pulse propagation
ZA913922B (en) Method for preventing a second heart attack employing an hmg coa reductase inhibitor
DE3881373D1 (de) Hmg-coa-reduktase-hemmer.
GB9002016D0 (en) Hmg coa reductase inhibitor and method for lowering serum cholesterol
AU643085B2 (en) Polymerization inhibitor and inhibiting method for vinyl compound
GB2284054B (en) Method for range determination
AU645142B2 (en) Corrosion inhibition
AU643308B2 (en) 2-(9-fluorenonyl)-carbapenem
AU8694291A (en) Ester inhibitors
AU7037994A (en) A method of galvanising
GB2251562B (en) Method and assembly for compensating the bending of a doctor blade beam
IE882653L (en) HMG CoA REDUCTASE INHIBITORS
AU5550990A (en) Novel hmg coa reductase inhibitors
GB9303051D0 (en) 17b-nmonosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-en-3-one testosterone-5-alpha reductase inhibitors
EP0468974A4 (en) Novel hmg-coa reductase inhibitors
ZA912509B (en) 3-hydroxy-3-methylglutaryl coenzyme a reductase(hmg-coa reductase)inhibitors
IE862071L (en) HMG CoA REDUCTASE INHIBITORS
AU6931196A (en) 4-{2-(pyrimidin-4-oxy- or 4-ylamino)-ethyl}-phenyl-oximes